Gut Bacteria Imbalance Doubles Death Risk in Advanced Colorectal Cancer

For someone facing advanced colorectal cancer, doctors already weigh a long list of factors to gauge what's ahead: tumor stage, genetics, how surgery went. A new study out of China points to another one hiding in plain sight, the trillions of bacteria living in the gut. Patients whose gut microbiome had drifted out of its normal balance were not only less likely to respond to first-line chemotherapy, they were more than twice as likely to die during the study's multi-year follow-up. It's one of the more concrete signals yet that what's happening in the colon isn't just a bystander to the cancer growing inside it.

Key takeaways:

• Among 124 patients with stage IIIB to IV colorectal cancer, those with gut microbial dysbiosis (an imbalance in the mix and diversity of gut bacteria) had more than double the risk of death (hazard ratio 2.31) over a median 32.5-month follow-up, independent of age, tumor markers and chemo regimen.
• Patients with a more typical gut microbiome responded better to first-line chemotherapy: a higher share achieved an objective response or disease control, regardless of RAS or BRAF mutation status.
• This is a single-center, retrospective study in Chinese patients; it shows an association, not proof that changing gut bacteria would improve outcomes.

Gut Microbial Dysbiosis Predicts Colorectal Cancer Survival

Patients with advanced colorectal cancer (cancer that has spread beyond the primary tumor site, stage IIIB through IV) whose gut bacteria showed dysbiosis, meaning lower diversity and a shift toward harmful species, had significantly worse outcomes than patients with a more balanced gut microbiome, according to a retrospective cohort study of 124 patients published in the World Journal of Gastrointestinal Oncology. After statistically adjusting for age, a tumor marker called carcinoembryonic antigen (CEA), and chemotherapy regimen, dysbiosis remained an independent predictor of worse overall survival, with a hazard ratio of 2.314 (95% confidence interval 1.258 to 4.259, p = 0.007). In plain terms, patients with dysbiosis were roughly twice as likely to die at any given point during the study as patients without it.

The dysbiosis group's gut communities looked distinctly different under 16S rRNA sequencing (a DNA-based technique that identifies which bacterial species are present in a stool sample): lower species diversity, less of the beneficial phylum Firmicutes, and more of the phyla Fusobacteria, Bacteroidetes and Proteobacteria. Their stool also had markedly lower levels of short-chain fatty acids (beneficial molecules gut bacteria produce by fermenting fiber) and higher levels of secondary bile acids, a byproduct linked to intestinal inflammation. All of these differences were statistically significant (p < 0.001).

Why This Matters for Colorectal Cancer Patients

Colorectal cancer is one of the most commonly diagnosed cancers worldwide, and advanced-stage disease still carries a poor long-term outlook even with standard treatment. This study adds gut microbiome status to a short list of factors researchers have linked to colorectal cancer diagnosis, prognosis and treatment response: patients in the dysbiosis group also had more poorly differentiated tumors, more stage IV disease at diagnosis, and higher rates of vascular and nerve invasion than patients with typical gut bacteria.

The chemotherapy findings may matter even more for someone currently in treatment. Among the 96 patients who received first-line chemotherapy (mostly the regimens FOLFOX and CAPOX, plus FOLFIRI), both the objective response rate and the disease control rate were significantly higher in patients with a normal gut microbiome than in those with dysbiosis (p < 0.05). That gap held up regardless of whether a patient's tumor carried a RAS or BRAF mutation, mutations that oncologists already use to guide treatment choices, suggesting the microbiome effect isn't just standing in for genetics.

How the Study Tracked 124 Patients Over Five Years

Researchers at the First Hospital of Jiaxing in China retrospectively enrolled 124 patients with confirmed stage IIIB to IV colorectal cancer, treated between September 2020 and September 2025. Before any anti-tumor treatment began, each patient gave a fresh stool sample, which was sequenced to profile their gut bacteria. Patients were then split into a "dysbiosis" group or a "normal flora" group based on preset thresholds for microbial diversity and the relative abundance of known beneficial versus harmful bacteria. The two groups were well matched on age, sex, tumor location, tumor marker levels and treatment regimen going in, which strengthens the case that the survival gap tracked with the microbiome rather than with some other imbalance between groups. Patients were followed for a median of 32.5 months, with a 100% follow-up rate and no patients lost to tracking, unusually complete for a retrospective study.

What This Could Mean If You or a Loved One Has Colorectal Cancer

This study does not establish that taking a probiotic, changing your diet or otherwise trying to "fix" your gut bacteria will improve chemotherapy response or survival. No intervention was tested here. What it does suggest is that gut microbiome profiling could eventually help identify, at diagnosis, which advanced colorectal cancer patients are at higher risk and might benefit from closer monitoring or more aggressive treatment planning. If you or someone you're caring for has advanced colorectal cancer, this is a reasonable study to bring up with an oncologist as a talking point on emerging prognostic research, not as a basis for a specific supplement or diet change, which the study doesn't support.

What the Study Doesn't Prove Yet

This was a single-center, retrospective study conducted in one hospital in China, a design that is prone to selection bias and can't establish that dysbiosis directly causes worse outcomes rather than simply accompanying more aggressive disease. The authors also note they didn't trace the biological pathway connecting microbial metabolites to tumor behavior in detail, and no prospective trial has tested whether correcting a patient's dysbiosis actually changes their chemotherapy response or survival.

What Comes Next for Microbiome-Based Cancer Prognosis

The study's authors frame gut dysbiosis as a candidate biomarker for risk stratification and call for the obvious next steps: larger, multi-center, prospective studies to confirm the link, and deeper analysis of the metabolic pathways involved, which the study already flags short-chain fatty acids and secondary bile acids as suspects. Other researchers have begun mapping how specific pathogens like Fusobacterium nucleatum drive chemotherapy resistance in colorectal tumors, work that could eventually point toward microbiome-targeted interventions tested in trials for patients identified as high-risk. None of that has happened yet.

Common Questions

Does gut dysbiosis cause colorectal cancer to spread faster? This study shows a strong statistical association, not proof of cause and effect. Researchers propose that pathogenic bacteria and their metabolic byproducts may promote tumor aggressiveness and blunt chemotherapy, but that mechanism wasn't directly tested here.

Could taking probiotics improve chemotherapy response? Not based on this study. No patients received a microbiome-targeting intervention; the findings are purely observational, and no probiotic or supplement should be assumed to replicate the "normal flora" pattern seen in better-responding patients.

How was gut dysbiosis measured in this study? Researchers sequenced the 16S rRNA gene, a standard DNA-based method for identifying bacterial species in a stool sample, then classified patients based on their microbial diversity and the relative abundance of known beneficial and harmful bacteria.

Does this apply to earlier-stage colorectal cancer? This study only enrolled patients with stage IIIB through IV (advanced) disease, so the findings can't be extended to earlier-stage colorectal cancer without further research.

References

Yun Wang, Yi-Wei Dong, Yang Wang, Yao-Yu Jin, Yu-Xuan Zhou, Yan Li (2026). Association between gut microbial dysbiosis and clinical prognosis of advanced colorectal cancer. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.122497